Skip to navigation Skip to content



About this Medication
  • Brand Name: Aubagio® (U.S.) (oh-BAH-gee-oh)
  • Chemical Name: teriflunomide (ter-i-FLOO-noe-mide)
  • Usage in MS: Disease-Modifying Agent
  • Generic Available: Yes

This is an oral medication in tablet form.



Aubagio® (teriflunomide), a pyrimidine synthesis inhibitor, is an oral compound that inhibits the function of specific immune cells that have been implicated in MS. It is related to leflunomide, a drug used to treat rheumatoid arthritis. Aubagio can inhibit a key enzyme required by white blood cells (lymphocytes) – which in turn reduces the proliferation of T and B immune cells that are active in MS and also inhibits the production of immune messenger chemicals by T cells.

Aubagio was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsing forms of multiple sclerosis to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, in adults.

Click here to see the FDA prescribing information for healthcare professionals.

Click here to see the FDA Medication Guide for patients.


MS One to One
1-855-MSOne2One (1-855-676-6326)

Financial Assistance Program

MS One to One
1-855-MSOne2One (1-855-676-6326)


What You Need to Know About Aubagio®

This video features Dr. Jim Bowen and Dr. Lily Jung Henson discussing approved disease-modifying treatment, Aubagio® (teriflunomide) and was created in 2013. To learn more about Aubagio® and other disease modifying treatment options, download the Consensus on Disease-Modifying Therapies.

Watch Now


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.